Amylin receptor agonism enhances the effects of liraglutide in protecting against the acute metabolic side effects of olanzapine.

ABSTRACT: Olanzapine is a second-generation antipsychotic (AP) used in the management of schizophrenia. Although effective at reducing psychoses, APs cause rapid hyperglycemia, insulin resistance, and dyslipidemia, an effect mediated in part by glucagon. We tested if amylin, a hormone that reduces glucagon, or the amylin receptor agonist pramlintide would protect against acute olanzapine-induced impairments in glucose and lipid homeostasis alone or in combination with other glucose-lowering agents such as liraglutide. We demonstrated that pramlintide lowered olanzapine-induced increases in glucagon:insulin ratio with a trend to protect against excursions in blood glucose. There was an additive effect of pramlintide and liraglutide in protecting against olanzapine-induced hyperglycemia, which was mir

SUBMITTER: Medak KD 

PROVIDER: S-EPMC10767228 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature